Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASH

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Jun 30, 2022 1:04pm

131 Views

Post# 34794259

RE:RE:RE:NASH

It's just a fancy term for using a computer model to simulate co dictions and results. THTX had mentioned in the past they used in silico for some of their NASH research.

palinc2000 wrote: I was not faniliar with the term "" in silico model""
Scarlet's post tells me that THTX is still very much involved in Nash but is looking to make it right rather than fast...

palinc2000 wrote: https://pubs.acs.org/doi/10.1021/acs.chemrestox.0c00511

quote=scarlet1967]https://www.linkedin.com/posts/novadiscovery_casestudy-nash-modelingandsimulation-activity-6948189692622213120-7fMg?utm_source=linkedin_share&utm_medium=ios_app